Transatlantic guidelines on dyslipidemia and cardiovascular risk: key differences across the pond

Area of Science:

• Cardiology
• Lipid Management
• Clinical Guidelines

Background:

• Atherosclerotic cardiovascular disease (ASCVD) remains a leading cause of mortality worldwide.
• Effective lipid management is crucial for preventing ASCVD events.
• Recent guideline updates from major cardiovascular societies aim to refine treatment strategies.

Purpose of the Study:

• To compare and contrast the key recommendations of the 2018 AHA/ACC and 2019 ESC/EAS guidelines for managing blood cholesterol and dyslipidemias.
• To review the evidence underpinning these guidelines.
• To provide expert opinion on the clinical implications of these guidelines.

Main Methods:

• Comparative analysis of the 2018 AHA/ACC Multisociety Guideline on the Management of Blood Cholesterol and the 2019 ESC/EAS Guidelines for the Management of Dyslipidemias.
• Literature review of the evidence supporting guideline recommendations.
• Expert interpretation and synthesis of guideline content.

Main Results:

• Both guidelines advocate for aggressive lipid-lowering therapy in high-risk patients, including those with ASCVD, severe hypercholesterolemia, familial hypercholesterolemia, or diabetes.
• Risk stratification may be enhanced by considering risk enhancers/modifiers beyond traditional risk factors.
• The guidelines differ primarily in the classification and management strategies for very-high-risk ASCVD patients, with ESC/EAS supporting more aggressive use of ezetimibe and PCSK9 inhibitors.

Conclusions:

• Both the AHA/ACC and ESC/EAS guidelines provide robust, evidence-based frameworks for cholesterol management.
• Implementation of either guideline is expected to improve ASCVD outcomes compared to current practices.
• The differing approaches to very-high-risk patients warrant careful consideration for personalized treatment strategies.